Advances in Proteomics & Metabolomics 2022 Online Symposium

Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling

Now On Demand | Presented by Technology Networks

Greater use of small molecule biomarkers in drug development is needed to transform efficiency and success rates, by driving deeper understanding of how non-genetic factors influence disease pathobiology and drug responsiveness. In this session, Sapient will discuss how its next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems enable untargeted small molecule biomarker discovery at unprecedented speed and at population scale, with the ability to assay >11,000 circulating factors per biosample in <1 minute per sample run.

Learn how these systems enable a new scale of discovery, with 4D chemical characterization of known and unknown molecules, and how they are integrated into a larger discovery pipeline to allow for rapid biomarker cross validation across large, diverse populations. Review examples of the robust data generated to reveal specific biomarkers that can be used to align patients, disease biology, and specific therapies.

Access this talk on-demand, along with all the other symposium sessions detailing the latest advancements in translational proteomics and metabolomics. Click to watch now.